AIM ImmunoTech CEO ties Ampligen antiviral research to military biodefense in Breaking Defense op-ed

AIM ImmunoTech Inc. disclosed in an 8-K dated August 11, 2026 that the online media company Breaking Defense published an article authored by Thomas K. Equels, the company's Chief Executive Officer, on that date.¹ The piece, titled "Biodefense is force protection: Ready today, prepared for tomorrow," was furnished as Exhibit 99.1 to the filing.

The article argues that Ampligen (rintatolimod) could serve as a broad-spectrum antiviral against Ebola virus disease, and separately reviews the drug's history and potential use against COVID-19 and related viruses.¹

On Ebola, the article cites preclinical work conducted with government funding at biosafety level 4 laboratories run by the U.S. Army Medical Research Institute of Infectious Diseases, involving Ampligen. As described in the peer-reviewed journal Antiviral Research, the study showed 100% survival in one rintatolimod-treated cohort in a lethal mouse model, versus complete mortality among untreated controls.¹ The article notes the data support further study of rintatolimod's mechanism of action as a possible broad-spectrum tool across Ebola variants including Bundibugyo, and that AIM is seeking government support for such research.¹

On coronaviruses, the article points to government-funded research at Utah State University's Institute for Antiviral Research conducted between the 2003 SARS outbreak and the COVID-19 outbreak, published in Antiviral Chemistry & Chemotherapy and Virology.¹

The filing includes a disclosure stating Ampligen is not FDA-approved for Ebola virus disease, Bundibugyo virus disease, coronaviruses, or any biodefense indication.¹ The filing also cautions that forward-looking statements involve uncertainties including the risk that preclinical results may not be replicated in clinical trials, regulatory uncertainties, dependence on government funding, limited financial resources, and competitive and market conditions.¹